Cargando…

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

BACKGROUND: Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive for aquaporin-4 (AQP4)–immunoglobulin (Ig) G were demonstrated in the 28-week randomized controlled period of the N-MOmentum study. OBJECTIVE: To assess efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rensel, Mary, Zabeti, Aram, Mealy, Maureen A, Cimbora, Daniel, She, Dewei, Drappa, Jorn, Katz, Eliezer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024030/ https://www.ncbi.nlm.nih.gov/pubmed/34595983 http://dx.doi.org/10.1177/13524585211047223

Ejemplares similares

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021)

Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders
por: Yan, Li, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis
por: Yan, Li, et al.
Publicado: (2021)

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
por: Cree, Bruce AC, et al.
Publicado: (2021)

Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Inebilizumab: First Approval
por: Frampton, James E.
Publicado: (2020)

Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial
por: Perugino, Cory, et al.
Publicado: (2023)

Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis
por: Sridhar, Siddharth, et al.
Publicado: (2014)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Neuromyelitis optica pathogenesis and aquaporin 4
por: Graber, David J, et al.
Publicado: (2008)

Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica
por: Paul, Friedemann, et al.
Publicado: (2007)

The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders
por: Chen, Yihong, et al.
Publicado: (2020)

Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
por: Weinshenker, Brian G, et al.
Publicado: (2023)

Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study
por: Chien, Claudia, et al.
Publicado: (2019)

Corrigendum: The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders
por: Chen, Yihong, et al.
Publicado: (2020)

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
por: Jarius, S., et al.
Publicado: (2008)

Patterns of Antibody Binding to Aquaporin-4 Isoforms in Neuromyelitis Optica
por: Mader, Simone, et al.
Publicado: (2010)

The neuromyelitis optica presentation and the aquaporin-4 antibody in HIV-seropositive and seronegative patients in KwaZulu-Natal, South Africa
por: Bhigjee, Ahmed I., et al.
Publicado: (2017)

Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders
por: Oertel, Frederike Cosima, et al.
Publicado: (2023)

Investigating paraneoplastic aquaporin‐4‐IgG‐seropositive neuromyelitis optica spectrum disorder through a data‐driven approach
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Immunodominant T Cell Determinants of Aquaporin-4, the Autoantigen Associated with Neuromyelitis Optica
por: Nelson, Patricia A., et al.
Publicado: (2010)

Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks
por: Sato, Douglas Kazutoshi, et al.
Publicado: (2014)

Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder
por: Abdel-Mannan, Omar, et al.
Publicado: (2022)

Neuromyelitis optica spectrum disorder with active replication of hepatitis B virus and seropositive anti-aquaporin-4 antibody: A case report
por: Lei, Jiaying, et al.
Publicado: (2021)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
por: Schanda, Kathrin, et al.
Publicado: (2015)

Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity
por: Pisani, Francesco, et al.
Publicado: (2013)

Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
por: Chen, Ding, et al.
Publicado: (2016)

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker
por: Aktas, Orhan, et al.
Publicado: (2021)

Detection of anti-aquaporin-4 autoantibodies in the sera of Chinese neuromyelitis optica patients★
por: Li, Miao, et al.
Publicado: (2013)

Evaluation of Clinical Interest of Anti-Aquaporin-4 Autoantibody Followup in Neuromyelitis Optica
por: Chanson, Jean-Baptiste, et al.
Publicado: (2013)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
por: Waters, Patrick, et al.
Publicado: (2016)

The single nucleotide polymorphism site of aquaporin-4 gene in patients with neuromyelitis optica
por: Wang, Qing-Song, et al.
Publicado: (2017)

COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica
por: Cabal-Herrera, Ana Maria, et al.
Publicado: (2021)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Functional Characterization of Aquaporin-4 Specific T Cells: Towards a Model for Neuromyelitis Optica
por: Kalluri, Sudhakar Reddy, et al.
Publicado: (2011)

Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica
por: Jones, Melina V., et al.
Publicado: (2015)

The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica
por: Cheng, Chen, et al.
Publicado: (2016)

Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder
por: Asato, Yuko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4qvdi1fpf3k23qv10gg2cis9k3